Enter assignee name

% Expired Patents = 30.0

CIPO Patents = 2

EPO Patents = 2

Forward Citations = 23

Loading Chart...

7 inventors (with patents filed for the assignee):

Frank Tegtmeier (10 out of 12 patents)

Peter Scheurer (7 out of 7 patents)

Reinhard Schinzel (7 out of 7 patents)

4. Robert Doblhofer (3 out of 4 patents)

5. Ulrich Walter (1 out of 4 patents)

6. Kirstin Wingler (1 out of 1 patent)

7. Harald Schmidt (1 out of 5 patents)

10 patents: Sort by Forward Citations

1. 12458644 - Process for preparing solutions comprising biopterin derivatives (2025-11-04),

2. 11717522 - Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions (2023-08-08),

3. 10925877 - Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions (2021-02-23),

4. 10493075 - Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions (2019-12-03),

5. 10016431 - Solid pharmaceutical compositions comprising biopterin derivatives and uses of suchcompositions (2018-07-10),

6. 9895372 - Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions (2018-02-20),

7. 9422289 - Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species (2016-08-23),

8. 9382252 - Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species (2016-07-05),

9. 8236809 - Substituted 1,2,3-triazolopyrimidines for the inhibition of NAD(P)H oxidases and platelet activation (2012-08-07),

10. 7541360 - 4-amino-7,8-dihydropteridines, pharmaceutical compositions containing them and their use for the treatment of diseases which are caused by an increased nitric oxide level (2009-06-02),

Vasopharm GmbH is a biopharmaceutical company specializing in the development of innovative treatments for neurological diseases. Their focus is on developing novel therapies to target the underlying causes of brain damage and improve patient outcomes. With a strong commitment to research and development, Vasopharm is dedicated to advancing the field of neurology and improving the lives of patients worldwide.

This text is generated by artificial intelligence and may not be accurate.